Aceso Life Science's (HKG:0474) attributable loss narrowed to HK$137 million in the half-year ended Sept. 30 from HK$207 million in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.
Loss per share at the construction machinery company narrowed to HK$0.0191 from HK$0.0285 in the previous year.
Revenue declined to HK$109 million from HK$113 million a year earlier.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。